Recent Updates
Recently added Catalysts

Obsessive Compulsive Disorder: one US-listed biotech with a clinical-stage programme

Neurology & PsychiatryUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$16.1Buniverse median $1.20B
Allocated capital$2.7B$16.1B competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank76/299crowding rank 115

Obsessive Compulsive Disorder is uncontested. Neurocrine Biosciences (NBIX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Valbenazine in phase 2.

There is no public comparable to price it against. NBIX spreads its $16.1B market cap across 6 indications, so $2.7B of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$2.7B of allocated capital sits in Obsessive Compulsive Disorder, ranking it 76th of 299 indications by the money committed to it.

Companies developing drugs for Obsessive Compulsive Disorder 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
NBIXNeurocrine BiosciencesValbenazinePhase 21$16.1BNo6 31 Dec 2027

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Obsessive Compulsive Disorder counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Obsessive Compulsive Disorder has one competitor and a median of $16.1B.

Neurology & Psychiatry

Neurology & Psychiatry holds $120B of the map's capital, 17.9% of the total, spread across 46 indications and 58 companies. 19 of those indications have more than one company competing.

See every Neurology & Psychiatry indication on the map

Related indications in Neurology & Psychiatry

Chorea1 company · $2.7B · median $16.1BUncontestedExcessive Daytime Somnolence1 company · $2.7B · median $10.9BUncontestedSmoking Cessation1 company · $2.7B · median $10.9BUncontestedNarcolepsy Type 11 company · $2.6B · median $7.9BUncontestedParkinson's Disease5 companies · $2.5B · median $1.3BConcentrated betAlzheimer's Disease5 companies · $2.9B · median $397MOrphan cornerHuntington's Disease2 companies · $2.4B · median $2.8BConcentrated betFriedreich Ataxia5 companies · $3.2B · median $941MOrphan corner

Obsessive Compulsive Disorder pipeline questions

Which biotech companies are developing drugs for Obsessive Compulsive Disorder?

Neurocrine Biosciences (NBIX, Valbenazine, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Obsessive Compulsive Disorder.

How advanced is the Obsessive Compulsive Disorder pipeline?

Of the 1 clinical-stage programme in Obsessive Compulsive Disorder, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Obsessive Compulsive Disorder?

No. NBIX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Obsessive Compulsive Disorder, which is why the indication is classified as uncontested.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map